Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 2024Cancer ReportsOpen Access

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBianca SerioFGFrancesco GrimaldiLALucia Ammirati

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Serio et al. (2024) studied this question.

synapsesocial.com/papers/68e71030b6db6435876898e0https://doi.org/10.1002/cnr2.2044
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia2023 · 38 citations
  2. 2Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults2020 · 31 citations
  3. 3Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i>-mutated AML: results from the AMLSG 09-09 trial2020 · 123 citations
  4. 4Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel2016 · 5,973 citations
  5. 5Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia2023 · 10 citations